AstraZenecavsJohnson & Johnson

AZN and JNJ stock compared: price, dividend, valuation and results, from SEC filings.

Over the last year, with dividends, AZN moved -0.9% and JNJ +36.5%. Dividend yield: AZN none, JNJ 1.98%.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AZN–

    JNJ$644B

  • Revenue, 12 months

    AZN$58.7B

    JNJ$99.3B

    JNJ is 1.7 times AZN

  • Net income, 12 months

    AZN$10.2B

    JNJ$16.1B

    JNJ is 1.6 times AZN

  • Operating margin

    AZN23.4%

    JNJ–

  • ROIC

    AZN14.8%

    JNJ12.4%

    2.4 points apart

  • P/E

    AZN–

    JNJ40.0

  • Dividend yield

    AZN0.0%

    JNJ2.0%

    2.0 points apart

  • 5-year return

    AZN+70.7%

    JNJ+89.1%

    18.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AZN+70.7%

JNJ+89.1%

10015020020222023202420252026
Returns by period
PeriodAZNWith dividendsJNJWith dividends
1 year since November 18, 2025-0.9%Price -1.9%+36.5%Price +33.5%
3 years since November 17, 2023+44.3%+13.0% a yearPrice +36.9%+94.2%+24.8% a yearPrice +78.3%
5 years since November 18, 2021+70.7%+11.3% a yearPrice +54.8%+89.1%+13.6% a yearPrice +64.5%
10 years since November 21, 2016+321.9%+15.5% a yearPrice +221.2%+202.6%+11.7% a yearPrice +132.3%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AZNAstraZenecaJNJJohnson & Johnson

Valuation

AZNJNJ
Valuation
Price$175.63$267.11
Market value–$644B
Enterprise value (EV)–$671B
P/E–40.0
P/E, 5-year median32.221.9
P/B–7.9
EV/EBIT–37.8
Free cash flow yield–3.2%

Results and growth

AZNJNJ
Results and growth
Revenue, 12 months$58.7B$99.3B
Net income, 12 months$10.2B$16.1B
Free cash flow, 12 months$11.8B$20.6B
Earnings per share, 12 months$6.54$6.59
Revenue growth, year on year8.6%6.1%
Revenue growth a year, past+17.2%over 5 years+2.7%over 5 years
EPS growth a year, past+21.8%over 5 years+14.9%over 5 years

Margins and returns on capital

AZNJNJ
Margins and returns on capital
Gross margin81.9%67.6%
Operating margin23.4%–
Net margin17.4%16.2%
ROIC14.8%12.4%
ROE21.0%19.7%

Balance sheet

AZNJNJ
Balance sheet
Cash$5.7B$17.2B
Total debt$26.5B$44.7B
Net debt / EBITDA1.11.1
Interest cover8.1×18.0×

Dividends and buybacks

AZNJNJ
Dividends and buybacks
Dividend yield–2.0%
Dividend per share, 12 months$3.13$5.28
Dividend growth a year, past+2.3%over 5 years+5.3%over 5 years
Buyback yield–0.9%
Shareholder yield–2.9%

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AZN or JNJ

Didn't find what you were looking for?

Ask us
How did AZN and JNJ stock do over the last 10 years?

Since November 21, 2016, AZN's price moved +221.2% and JNJ's +132.3%. With dividends: AZN +321.9% (+15.5% a year), JNJ +202.6% (+11.7% a year). Past returns do not predict future ones.

Which pays the higher dividend, AZN or JNJ?

The dividend yield at today's price is none for AstraZeneca and 1.98% for Johnson & Johnson. Over the last twelve months they paid $3.13 and $5.28 per share.

Which has the higher profit margins, AstraZeneca or Johnson & Johnson?

Over the last twelve months, the net margin was 17.4% for AstraZeneca and 16.2% for Johnson & Johnson, and the operating margin 23.4% and –. Revenue was $58.7B and $99.3B.

Which is the better investment, AstraZeneca or Johnson & Johnson?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.